

Freedom of Information Request	FOI 22-529	18 <sup>th</sup> November 2022
--------------------------------	------------	--------------------------------

**A. How many patients have been treated with the following drugs in the past 4 months:**

- **Erenumab (Aimovig) - any disease**
- **Fremanezumab (Ajovy) - any disease**
- **Galcanezumab (Emgality) - any disease**
- **Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY**

The Health Board is only able to provide information by quantity and not by patient or diagnosis.

Please find below quantities dispensed to Neurology via hospital pharmacies for the above listed drugs for the period July 2022 to October 2022.

Type	Quantity
BOTULINUM TOXIN TYPE A (BOTOX) 200 units Injection 1 Vial Pack	15
BOTULINUM TOXIN TYPE A (BOTOX) 50 units Injection 1 Vial Pack	6
BOTULINUM TOXIN TYPE A (DYSPORE) 300 units Injection 1 Vial Pack	21
BOTULINUM TOXIN TYPE A (DYSPORE) 500 units Injection 2 Vial Pack	25
BOTULINUM TOXIN TYPE A (XEOMIN) 100 units Injection 1 Vial Pack	29
BOTULINUM TOXIN TYPE A (XEOMIN) 200 units Injection 1 Vial Pack	32
BOTULINUM TOXIN TYPE A (XEOMIN) 50 units Injection 1 Vial Pack	12
ERENUMAB 140 mg in 1mL Pre-Filled Pen 1 Pre-Filled Pen Pack	10
ERENUMAB 70 mg in 1mL Pre-Filled Pen 1 Pre-Filled Pen Pack	30
FREMANEZUMAB (AJOVY) 225 mg in 1.5mL Pre-Filled Pen 1 Pre-Filled Pen Pack	6
GALCANEZUMAB 120 mg in 1mL Pre-Filled Pen 1 Pre-Filled Pen Pack	547

**B. How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:**

<b>Drugs</b>	<b>Chronic Migraine (15+ headache days per month)</b>	<b>Episodic Migraine (15+ headache days per month)</b>
Erenumab	-	-
Fremanezumab	-	-
Galcanezumab	-	-
Botulinum Toxin	-	-

The Health Board does not record this information centrally. In order to provide the information requested, we would be required to review every patient record for the last months. The Health Board has established that to do this, it would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000, which is currently £450. As you will be aware this is not an exemption which requires us to consider the application of the public interest test.